panel-2-ip-deal-making-in-life-sciences
27 May 2026VideosRegulation & IndustryJohn Rearick, Cooley | Sarah Hogan, Cooley | Mark Shtilerman, Deerfield Management | Jennifer Burdman, Sauvegarder Investment Management | Kumar Govindaswamy, Kymera Therapeutics

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Regulation & Industry
5 October 2026   Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection.
Regulation & Industry
1 October 2026   LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.
Regulation & Industry
30 September 2026   The Third Circuit has upheld Thomson Reuters’ victory over Ross Intelligence in the first US appellate ruling on whether AI training can qualify as fair use. With the court’s reasoning still sealed, the case could have significant implications for AI developers using copyrighted content to build competing products.